Centre of Biotechnology, Faculty of Science, University of Allahabad, Allahabad, India.
Eur J Drug Metab Pharmacokinet. 2023 Sep;48(5):515-529. doi: 10.1007/s13318-023-00849-1. Epub 2023 Sep 1.
Messenger RNA (mRNA) has emerged as a new therapeutic agent for the prevention and treatment of a wide range of diseases. The recent achievement of the two lipid nanoparticle-mRNA vaccines developed by Moderna and Pfizer-BioNTech against coronavirus 2019 (COVID-19) disease in record time highlights the huge potential of mRNA technology and reshaping the landscape of vaccine development and the future of gene therapies. Challenges related to translational efficacy, mRNA stability, immunogenicity, and ensuring the quality of final products have been significantly improved by recent advancements in mRNA engineering and delivery. Thus, the present review aims to provide the latest innovations that incrementally overcome these issues and future directions in the context of ongoing clinical trials against infectious diseases and beyond.
信使 RNA（mRNA）已成为预防和治疗多种疾病的新型治疗药物。最近，Moderna 和辉瑞-BioNTech 开发的两种针对 2019 年冠状病毒病（COVID-19）的脂质纳米颗粒-mRNA 疫苗在创纪录的时间内取得了成功，这突显了 mRNA 技术的巨大潜力，并重塑了疫苗开发和基因治疗的未来。通过最近在 mRNA 工程和传递方面的进展，与翻译功效、mRNA 稳定性、免疫原性以及确保最终产品质量相关的挑战得到了显著改善。因此，本综述旨在提供最新的创新，逐步克服这些问题，并为正在进行的传染病临床试验及其他领域提供未来方向。
